Make Better Decisions - Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

Get the Book: Make Better Decisions

Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

PDF eBook: Just $10 Get Print Book on Amazon

Serving leading biopharmaceutical companies globally:

Johnson and Johnson
Dow
Boehringer Ingelheim
Baxter
Mallinckrodt
Express Scripts

Last Updated: October 20, 2019

DrugPatentWatch Database Preview

REQUIP XL Drug Profile

See Plans and Pricing

« Back to Dashboard

When do Requip Xl patents expire, and when can generic versions of Requip Xl launch?

Requip Xl is a drug marketed by Glaxosmithkline Llc and is included in one NDA. There are two patents protecting this drug and seven Paragraph IV challenges.

This drug has fifty-one patent family members in twenty-seven countries.

The generic ingredient in REQUIP XL is ropinirole hydrochloride. There are fourteen drug master file entries for this compound. Twenty-eight suppliers are listed for this compound. Additional details are available on the ropinirole hydrochloride profile page.

Drug patent expirations by year for REQUIP XL
Drug Prices for REQUIP XL

See drug prices for REQUIP XL

Recent Clinical Trials for REQUIP XL

Identify potential brand extensions & 505(b)(2) entrants

SponsorPhase
Titan PharmaceuticalsPhase 1/Phase 2
Vanderbilt University Medical CenterPhase 4
Seoul National University HospitalPhase 4

See all REQUIP XL clinical trials

Recent Litigation for REQUIP XL

Identify potential future generic entrants

District Court Litigation
Case NameDate
Sanofi-Aventis v. Wockhardt Limited2008-03-14
Plaintiff(s) v. Defendant(s)2008-01-31
Sanofi-Aventis v. Actavis South Atlantic LLC2007-09-21

See all REQUIP XL litigation

Pharmacology for REQUIP XL
Drug ClassNonergot Dopamine Agonist
Mechanism of ActionDopamine Agonists
Synonyms for REQUIP XL
030PYR8953
1,3-Dihydro-4-(2-(dipropylamino)ethyl)-2H-indol-2-one monohydrochloride
2(H)-Indol-2-one, 4-(2-(dipropylamino)ethyl)-1,3-dihydro-, monohydrochloride
2H-Indol-2-one, 1,3-dihydro-4-(2-(dipropylamino)ethyl)-, monohydrochloride
2H-Indol-2-one, 4-(2-(dipropylamino)ethyl)-1,3-dihydro-
2H-Indol-2-one,4-[2-(dipropylamino)ethyl]-1,3-dihydro-
374R208
374R219
4-(2-(Dipropylamino)ethyl)-1,3-dihydro-2H-indol-2-one
4-(2-(Dipropylamino)ethyl)-2-indolinone monohydrochloride
4-(2-(dipropylamino)ethyl)indolin-2-one
4-(2-(Dipropylamino)ethyl)indolin-2-one hydrochloride
4-(2-di-n-propylaminoethyl)-2(3H)-indolone hydrochloride
4-(2-di-n-propylaminoethyl)-2(3H)indolone hydrochloride
4-(2-dipropylaminoethyl)-1,3-dihydroindol-2-one
4-(2-dipropylaminoethyl)-1,3-dihydroindol-2-one hydrochloride
4-[2-(Di-n-propylamino)ethyl]-2(3H)-indolone Hydrochloride
4-[2-(dipropylamino)ethyl]-1,3-dihydro-2H-indol-2-one
4-[2-(dipropylamino)ethyl]-1,3-dihydro-2H-indol-2-one hydrochloride
4-[2-(Dipropylamino)ethyl]-1,3-dihydro-2H-indol-2-one; 4-[2-(Dipropylamino)ethyl]indoline-2-one; Ropinirole; SKF 101468
4-[2-(dipropylamino)ethyl]-1,3-dihydroindol-2-one
4-[2-(dipropylamino)ethyl]-1,3-dihydroindol-2-one hydrochloride
4-[2-(dipropylamino)ethyl]-1,3-dihydroindol-2-one;hydrochloride
4-[2-(dipropylamino)ethyl]-1.3-dihydro-2H-indol-2-one
4-[2-(dipropylamino)ethyl]-2,3-dihydro-1h-indol-2-one
4-[2-(dipropylamino)ethyl]-2,3-dihydro-1H-indol-2-one hydrochloride
4-[2-(dipropylamino)ethyl]-3H-indol-2-ol
4-[2-(Dipropylamino)ethyl]2-indolinone
4-[2-(dipropylamino)ethyl]indolin-2-one
4-[2-(dipropylamino)ethyl]indolin-2-one hydrochloride
4CA-1107
91374-20-8
91374-20-8 (hydrochloride)
91374-20-8,91374-21-9(freebase)
91374-21-9
91374-21-9 (base)
91374-21-9 (Parent)
A843815
AB0009822
AB01563044_01
AB01563044_02
AB1004799
ABP000199
AC-735
AC-736
AC1L1JLL
AC1L2ABS
AC1Q3EQJ
ACT02690
Adartrel
AJ-08123
AKOS015843123
AKOS015844988
AN-15583
AN-15584
ANW-58872
API0004095
BC207366
BC226368
BCP02130
BCP09383
BDBM50020680
BIDD:GT0826
BRD-K15933101-003-01-2
BS-1020
C-33038
C07564
CAS-91374-21-9
CC-34286
CCG-205177
CCG-213346
CHEBI:8888
CHEBI:8889
CHEMBL1200411
CHEMBL589
CS-2864
CTK8B7890
CTK8D4279
D00784
D08489
D7ZD41RZI9
DB00268
DSSTox_CID_25195
DSSTox_GSID_45195
DSSTox_RID_80742
DTXSID50238533
DTXSID8045195
EBD38503
EU-0101101
FC0024
FT-0642200
FT-0652500
GTPL7295
HMS2093K04
HP-3000
HSDB 8252
HY-B0623A
I06-0692
I06-0693
JZP-7
KB-80420
KS-000011L6
KS-00002WRZ
L000520
Lopac-R-4152
Lopac0_001101
LP01101
LS-83828
LS-83890
M-1298
MCULE-1333778454
MCULE-8190476072
MFCD01754173
MLS003899234
MolPort-003-666-598
MolPort-003-987-439
NCGC00015893-01
NCGC00015893-02
NCGC00015893-03
NCGC00015893-04
NCGC00015893-06
NCGC00094373-01
NCGC00096064-01
NCGC00096064-02
NCGC00261786-01
NP-201
NSC-758917
NSC758917
NVD-434
Pharmakon1600-01505178
R 4152
Repreve
Requi
ReQuip
Requip (TN)
ReQuip CR
ReQuip LP
ReQuip PR
ReQuip XR
ropinirol
Ropinirol [INN-Spanish]
ropinirole
Ropinirole (hydrochloride)
Ropinirole (USAN/INN)
Ropinirole [INN:BAN]
Ropinirole [USAN:INN:BAN]
Ropinirole for peak identification 1, EuropePharmacopoeia (EP) Reference Standard
Ropinirole for peak identification 2, EuropePharmacopoeia (EP) Reference Standard
Ropinirole HCl
Ropinirole hydrochloride
Ropinirole hydrochloride (JAN/USAN)
Ropinirole hydrochloride [USAN:USP]
Ropinirole hydrochloride [USAN]
Ropinirole hydrochloride, EuropePharmacopoeia (EP) Reference Standard
Ropinirole Hydrochloride, Pharmaceutical Secondary Standard; Certified Reference Material
Ropinirole hydrochloride, powder, >=98% (HPLC)
Ropinirole hydrochloride, United States Pharmacopeia (USP) Reference Standard
Ropinirole hydrochloride;
Ropinirole hydrochloride/
Ropinirolhydrochloride
Ropinirolum
Ropinirolum [INN-Latin]
Ropitor (TN)
s3189
SC-16286
SCHEMBL35212
SCHEMBL40760
SK&F 101468
SK&F 101468-A
SK&F-101,468
SK&F-101468
SK&F-101468-A
SK&F-101468A
SKF 101468
SKF 101468 hydrochloride
SKF 101468; 4-[2-(dipropylamino)ethyl]-1,3-dihydro-2H-indol-2-one hydrochloride
SKF-101468
SKF-101468A
SMR001456484
SPECTRUM1505178
SR-01000076215
SR-01000076215-2
SR-01000076215-3
SR-01000076215-5
ST24042825
STL454344
SW199044-2
TC-010119
TC-030791
TL8005858
TL8005859
Tox21_110256
Tox21_110256_1
Tox21_501101
UHSKFQJFRQCDBE-UHFFFAOYSA-N
UNII-030PYR8953
UNII-D7ZD41RZI9
VA11691
XDXHAEQXIBQUEZ-UHFFFAOYSA-N
Z1695926158
ZINC2041

US Patents and Regulatory Information for REQUIP XL

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Glaxosmithkline Llc REQUIP XL ropinirole hydrochloride TABLET, EXTENDED RELEASE;ORAL 022008-001 Jun 13, 2008 AB RX Yes Yes   Start Trial   Start Trial Y   Start Trial
Glaxosmithkline Llc REQUIP XL ropinirole hydrochloride TABLET, EXTENDED RELEASE;ORAL 022008-005 Oct 31, 2008 AB RX Yes No   Start Trial   Start Trial   Start Trial
Glaxosmithkline Llc REQUIP XL ropinirole hydrochloride TABLET, EXTENDED RELEASE;ORAL 022008-003 Jun 13, 2008 AB RX Yes No   Start Trial   Start Trial Y   Start Trial
Glaxosmithkline Llc REQUIP XL ropinirole hydrochloride TABLET, EXTENDED RELEASE;ORAL 022008-002 Jun 13, 2008 DISCN Yes No   Start Trial   Start Trial Y   Start Trial
Glaxosmithkline Llc REQUIP XL ropinirole hydrochloride TABLET, EXTENDED RELEASE;ORAL 022008-006 Apr 10, 2009 AB RX Yes No   Start Trial   Start Trial   Start Trial
Glaxosmithkline Llc REQUIP XL ropinirole hydrochloride TABLET, EXTENDED RELEASE;ORAL 022008-003 Jun 13, 2008 AB RX Yes No   Start Trial   Start Trial Y   Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Expired US Patents for REQUIP XL

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Glaxosmithkline Llc REQUIP XL ropinirole hydrochloride TABLET, EXTENDED RELEASE;ORAL 022008-004 Jun 13, 2008   Start Trial   Start Trial
Glaxosmithkline Llc REQUIP XL ropinirole hydrochloride TABLET, EXTENDED RELEASE;ORAL 022008-001 Jun 13, 2008   Start Trial   Start Trial
Glaxosmithkline Llc REQUIP XL ropinirole hydrochloride TABLET, EXTENDED RELEASE;ORAL 022008-005 Oct 31, 2008   Start Trial   Start Trial
Glaxosmithkline Llc REQUIP XL ropinirole hydrochloride TABLET, EXTENDED RELEASE;ORAL 022008-002 Jun 13, 2008   Start Trial   Start Trial
Glaxosmithkline Llc REQUIP XL ropinirole hydrochloride TABLET, EXTENDED RELEASE;ORAL 022008-003 Jun 13, 2008   Start Trial   Start Trial
Glaxosmithkline Llc REQUIP XL ropinirole hydrochloride TABLET, EXTENDED RELEASE;ORAL 022008-006 Apr 10, 2009   Start Trial   Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >Patent No. >Patent Expiration
Paragraph IV (Patent) Challenges for REQUIP XL
Drugname Dosage Strength RLD Date
➤ Subscribe Extended-release Tablets 3 mg ➤ Subscribe   Start Trial
➤ Subscribe Extended-release Tablets 6 mg ➤ Subscribe   Start Trial
➤ Subscribe Extended-release Tablets 12 mg ➤ Subscribe   Start Trial
➤ Subscribe Extended-release Tablets 3 mg ➤ Subscribe   Start Trial
➤ Subscribe Extended-release Tablets 8 mg ➤ Subscribe   Start Trial
➤ Subscribe Extended-release Tablets 4 mg ➤ Subscribe   Start Trial
➤ Subscribe Extended-release Tablets 2 mg ➤ Subscribe   Start Trial

Supplementary Protection Certificates for REQUIP XL

Patent Number Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
0299602 SPC/GB96/040 United Kingdom   Start Trial PRODUCT NAME: ROPINIROLE, OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF, IN PARTICULAR THE HYDROCHLORIDE SALT; REGISTERED: UK 10592/0085 19960702
0299602 97C0036 Belgium   Start Trial PRODUCT NAME: CHLORHYDRATE DE ROPINIROLE (=ROPINIROLE); NAT. REGISTRATION NO/DATE: 981 IS 120 F 3 19970414; FIRST REGISTRATION: GB PL 10592/0085 19960702
>Patent Number >Supplementary Protection Certificate >SPC Country >SPC Expiration >SPC Description

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Baxter
AstraZeneca
Moodys
Express Scripts
McKinsey
Johnson and Johnson

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.